Multiple sclerosis and related disorders最新文献

{"title":"Real-world evidence from Türkiye on cancer risk and treatment exposure in multiple sclerosis: A histopathology-verified, registry-based study","authors":"Bilgin Öztürk ,&nbsp;Esra Taşkıran ,&nbsp;Serkan Demir ,&nbsp;Mustafa Murat Arat ,&nbsp;Aksel Siva ,&nbsp;Naim Ata ,&nbsp;Şuayip Birinci ,&nbsp;Murat Kürtüncü","doi":"10.1016/j.msard.2025.106547","DOIUrl":"10.1016/j.msard.2025.106547","url":null,"abstract":"<div><h3>Background</h3><div>Multiple sclerosis (MS) is a chronic, immune-mediated neurological disease with potential malignancy risks linked to disease-modifying therapies (DMTs) or immunosuppressants. This study aims to evaluate the epidemiology of malignancies in MS patients across T..rkiye and examine the impact of DMT/Immunosuppressant exposure on cancer risk.</div></div><div><h3>Methods</h3><div>The study used the Turkish Ministry of Health's electronic database to identify 82,025 MS patients through ICD-10 codes. Inclusion required ≥3 MS diagnoses or one MS diagnosis with at least one MS-specific DMT or immunosuppressants prescription which can be used for MS treatments (interferons, glatiramer acetate, fingolimod, natalizumab, ocrelizumab, alemtuzumab, dimethyl fumarate, teriflunomide, azathioprine, cyclophosphamide, methotrexate, mitoxantrone, mycophenolic acid, and rituximab). Malignancies were classified based on histopathological confirmation, using ICD-O codes in pathology reports. Systemic distributions of cancers in MS patients were analyzed by sex and compared with age-adjusted cancer incidence rates from the general population, as reported in the Turkish Ministry of Health database. We also compared cancer rates in patients exposed to a specific treatment with those observed in patients not exposed to that drug.</div></div><div><h3>Results</h3><div>Of the 82,025 patients with MS, 68.3 % were females and 31.7 % males, with an average diagnosis age of 34.8 ± 13.0 years. Among them, 1212 developed cancers, with females accounting for 73.5 % of the cases. Breast cancer was most common in females (29.2 %), while males primarily developed cancers of the respiratory, gastrointestinal, and urinary systems. The age-adjusted incidence rates of skin, female genital, breast, thyroid, and overall cancers in MS patients were similar to those reported in the general population. Notably, azathioprine use was linked to a significantly higher cancer risk (OR: 1.24, 95 % CI: 1.01–1.51, <em>p</em> = 0.032), whereas treatments like cladribine, dimethyl fumarate, and B-cell therapies showed a lower cancer incidence.</div></div><div><h3>Conclusions</h3><div>This study demonstrated that Multiple sclerosis does not appear to increase the risk of cancer compared to the general population and none of the MS treatments, except for azathioprine, were associated with an increased risk of cancer.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"100 ","pages":"Article 106547"},"PeriodicalIF":2.9,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring the emerging JC virus mutation and granule cell neuronopathy: A call for enhanced surveillance","authors":"Alexis Demas","doi":"10.1016/j.msard.2025.106545","DOIUrl":"10.1016/j.msard.2025.106545","url":null,"abstract":"","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"100 ","pages":"Article 106545"},"PeriodicalIF":2.9,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurofilament light chain predict disease activity and disability Progression in Korean patients with multiple sclerosis","authors":"Ki Hoon Kim ,&nbsp;Seung Ho Choo ,&nbsp;Ju-Hong Min ,&nbsp;Woojun Kim ,&nbsp;Jae-Won Hyun ,&nbsp;You-Ri Kang ,&nbsp;Ho Jin Kim ,&nbsp;Su-Hyun Kim","doi":"10.1016/j.msard.2025.106534","DOIUrl":"10.1016/j.msard.2025.106534","url":null,"abstract":"<div><h3>Background</h3><div>Serum neurofilament light chain (sNfL) has been identified as a useful biomarker for disease activity, prognosis, and treatment response in patients with multiple sclerosis (pwMS). However, its utility in Asian pwMS remains underexplored. This study investigates the predictive value of sNfL for disease activity and long-term disability as well as the applicability of Western-derived z-scores in Korean MS patients.</div></div><div><h3>Methods</h3><div>We analyzed 169 blood samples from 117 Korean pwMS across three referral hospitals. Baseline samples were obtained within one year of disease onset, with follow-up samples at least three months later. Age- and BMI-adjusted z-scores of baseline sNfL were analyzed for correlations with disease activity and prognosis, while delta z-scores —calculated as the difference between baseline and follow-up z-scores— were used to evaluate disease progression.</div></div><div><h3>Results</h3><div>Higher baseline sNfL level and z-scores were significantly associated with greater radiological disease activity, including T2 lesion burden and gadolinium-enhancing lesions. Patients with a baseline sNfL z-score &gt;2.86 had a 2.34-fold higher relapse risk within two years. Additionally, a delta z-score &lt;1, reflecting persistently elevated sNfL levels despite disease-modifying treatment, was strongly associated with an increased risk of reaching confirmed EDSS 3 (HR 15.56, 95 % CI 1.49–398.1).</div></div><div><h3>Conclusion</h3><div>These findings support sNfL as a useful biomarker for predicting disease activity and long-term outcomes in Korean pwMS. Elevated baseline sNfL levels reflect active disease and a higher risk of relapse, while persistently elevated sNfL following treatment initiation is associated with worse long-term disability outcomes.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"100 ","pages":"Article 106534"},"PeriodicalIF":2.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144147862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of gait parameters and chronic lower body pain in people with multiple sclerosis","authors":"Abbas Tabatabaei ,&nbsp;Tobia Zanotto ,&nbsp;Libak Abou ,&nbsp;Sharon G Lynch ,&nbsp;Jacob Sosnoff","doi":"10.1016/j.msard.2025.106526","DOIUrl":"10.1016/j.msard.2025.106526","url":null,"abstract":"<div><h3>Background</h3><div>Gait abnormalities are common in people with Multiple Sclerosis (pwMS). The relation between chronic pain in the lower body (CPLB) and gait impairment in Multiple Sclerosis is not clear.</div></div><div><h3>Objective</h3><div>To compare gait parameters between pwMS with and without CPLB. Methods: Forty pwMS (aged 54.3 <em>y</em> ± 7.7, 82.5 % women) took part in this crosssectional investigation. The revised Michigan Body Map was used to determine if the participants had CPLB. Participants were allocated to groups based on the presence of chronic pain in the lower body. Participants completed a standardized walk over a pressure-sensitive walkway (8 m), which was used to evaluate spatiotemporal gait parameters.</div></div><div><h3>Results</h3><div>Twenty-three and 17 pwMS were classified as having or not having CPLB, respectively. Participants with CPLB exhibited significantly slower gait speed (cm/s) (<em>p</em> = 0.01, mean difference (MD) 27.64 [95 % CI: 5.8 to 49.4]), fewer number of steps (<em>p</em> = 0.01, MD 14.20 [95 % CI: 2.90 to 25.50]), shorter steps (<em>p</em> = 0.04, MD 7 95 % CI: 14.2 to 25.5), prolonged steps (s) (<em>p</em> = 0.02, MD -0.11 [95 % CI:0.20 to -0.01]), lower percentage (<em>p</em> = 0.01, MD 2.70 [95 % CI: 0.50 to 4.9]) and higher variability (<em>p</em> = 0.01, MD 12.5 [95 % CI: 52.6 to 6.7]) of single-leg support (SLS) time compared to those without CPLB. The observed difference in gait speed exceeded the minimal clinically important differences.</div></div><div><h3>Conclusion</h3><div>This study revealed alterations in gait among pwMS with CPLB compared to those without pain. These findings can be leveraged in future studies to develop targeted rehabilitation strategies that focus on chronic pain in the lower body and gait.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"100 ","pages":"Article 106526"},"PeriodicalIF":2.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of dual-task training on inflammatory biomarkers, physical performance, fatigue, and quality of life in patients with multiple sclerosis","authors":"Sara Farajnia ,&nbsp;Hamid Rajabi ,&nbsp;Mehran Ghaffari ,&nbsp;Nahid Beladi-Moghadam ,&nbsp;Rana Fayazmilani","doi":"10.1016/j.msard.2025.106412","DOIUrl":"10.1016/j.msard.2025.106412","url":null,"abstract":"<div><h3>Objective</h3><div>This study investigates how combined aerobic-cognitive training and aerobic training impact some symptoms of MS.</div></div><div><h3>Methods</h3><div>Thirty RRMS patients with EDSS≤ 4 were randomly assigned to three groups: Brythonic training, aerobic training, and control. The training groups participated in ten weeks of home-based online training. The Brythonic group performed aerobic movements while reciting motivational words. The aerobic group performed the same movements without cognitive tasks. Interleukin 17 (IL-17), Interleukin 4 (IL-4), and Interleukin 17 to Interleukin 4 ratio (IL-4/IL-17), Time Up and Go (TUG) and Six-Minute Walk Test (6MWT), Modified Fatigue Impact Scale (MFIS), Multiple Sclerosis Quality of Life-54 Questionnaires (MSQOL-54) were measured before and after the 10-week.</div></div><div><h3>Results</h3><div>The Interleukin 17 variable significantly decreased in the Brythonic (<em>P</em> &lt; 0.0001). Nevertheless, Interleukin 4 and the Interleukin 17 and 4 ratios did not significantly differ. TUG and 6MWT variables substantially differed in training groups compared to the control. In MFIS, a significant difference was observed between the training and control groups. The MSQOL-54 variable substantially differed in mental health items in the Brythonic compared to the control group and in physical health items a significant difference was observed between the training and the control groups. Notably, in all the variables except the Interleukin 4 variable, the Brythonic significantly improved the results within the group.</div></div><div><h3>Conclusion</h3><div>This study concluded that engaging in any aerobic activity, even with moderate intensity, can improve some symptoms of MS such as fatigue and physical performance. Additionally, incorporating cognitive challenges into aerobic activity can cause a more significant effect, specifically on inflammatory factors.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"99 ","pages":"Article 106412"},"PeriodicalIF":2.9,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics associated with multiple sclerosis fatigue severity","authors":"Alexandra Balshi ,&nbsp;John P Dempsey ,&nbsp;Nova Manning ,&nbsp;Manuela Kriemler ,&nbsp;Sachin Kumbar ,&nbsp;Grace Leuenberger ,&nbsp;Larry Padilla ,&nbsp;Ursela Baber ,&nbsp;Jacob A Sloane","doi":"10.1016/j.msard.2025.106528","DOIUrl":"10.1016/j.msard.2025.106528","url":null,"abstract":"<div><h3>Background</h3><div>While clinical factors such as higher Expanded Disability Status Scale (EDSS) score, progressive disease subtype, older age, polysymptomatic onset, and depression have been shown to predict fatigue severity in people with multiple sclerosis (PwMS), their influences have not been evaluated simultaneously while controlling for broader MS severity risk factors and potential confounders.</div></div><div><h3>Objective</h3><div>To concurrently assess which previously established MS fatigue risk factors affect fatigue severity after adjusting for MS severity, obstructive sleep apnea (OSA), and stimulant use, and to validate these findings using a second fatigue scale.</div></div><div><h3>Methods</h3><div>We used multivariable linear regression to determine relationships between MS clinical data and MS-related fatigue as measured by the Modified Fatigue Impact Scale (MFIS) and the Fatigue Severity Scale (FSS), controlling for OSA and stimulant use.</div></div><div><h3>Results</h3><div>Polysymptomatic MS onset (MFIS β = 9.22, <em>p</em> = 0.027; FSS β = 5.90, <em>p</em> = 0.032), depression (MFIS β = 22.01, <em>p</em> &lt; 0.001; FSS β = 13.51, <em>p</em> = 0.003), and higher Expanded Disability Status Scale (EDSS) scores (MFIS β = 2.32, <em>p</em> = 0.028) were associated with more severe fatigue in PwMS.</div></div><div><h3>Conclusion</h3><div>Polysymptomatic MS onset, comorbid depression, and higher EDSS score remain independently associated with MS fatigue severity even when evaluated together adjusting for relevant controls. PwMS with these characteristics, especially those with all three, should be screened for fatigue and offered symptomatic treatment.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"100 ","pages":"Article 106528"},"PeriodicalIF":2.9,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144147863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of pulmonary function, physical activity and functional capacity of people with early-stage relapsing-remitting multiple sclerosis: A controlled study","authors":"Gürkan Demirtaş ,&nbsp;Tuba Can Akman ,&nbsp;Aslı Demirtaş ,&nbsp;Levent Sinan Bir","doi":"10.1016/j.msard.2025.106537","DOIUrl":"10.1016/j.msard.2025.106537","url":null,"abstract":"<div><h3>Background</h3><div>Although the respiratory function, physical activity, and functional capacity of people with Multiple Sclerosis (MS) decrease with the progression of the disease, there is not enough information about these parameters in early-stage people with Relapsing-Remitting MS (RRMS). This study aims to compare the respiratory function, physical activity, and functional capacity of low-disability people with RRMS who have no symptoms with healthy individuals.</div></div><div><h3>Methods</h3><div>Forty people with RRMS aged 18–60 and 40 healthy individuals with similar demographic characteristics were included in the study. Pulmonary Function Tests (PFT), International Physical Activity Questionnaire (IPAQ), and 6-minute walk test (6MWT) were used to determine respiratory functions, physical activity level, and functional capacity, respectively.</div></div><div><h3>Results</h3><div>The average age of people with RRMS and healthy individuals was 37.60 ± 9.20 and 37.88 ± 11.7 years, respectively (<em>p</em> &gt; 0.05). The median (min–max) value of the Expanded Disability Status Scale (EDSS) was 1 (1–3). When comparing the groups, FEV₁/FVC values were higher, and FVC ( % predicted), PEF, PEF (% predicted), MVV and MVV ( % predicted) values were lower in the MS group (<em>p</em> &lt; 0.05). While functional capacity was found to be low in people with MS (<em>p</em> &lt; 0.05), there was no difference between the two groups in terms of physical activity levels (<em>p</em> &gt; 0.05).</div></div><div><h3>Conclusion</h3><div>Respiratory functions and functional capacity are affected in people with RRMS from the early stages. Therefore, respiratory and functional capacity should be addressed from the early stages in the evaluation, medical treatment, and rehabilitation programs for people with MS.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"100 ","pages":"Article 106537"},"PeriodicalIF":2.9,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of oral and skin microbiota on multiple sclerosis risk and severity: A mendelian randomization analysis","authors":"Valeria Zancan ,&nbsp;Martina Nasello ,&nbsp;Selene Diamant ,&nbsp;Martina Marconi ,&nbsp;Rachele Bigi ,&nbsp;Roberta Reniè ,&nbsp;Maria Chiara Buscarinu ,&nbsp;Rosella Mechelli ,&nbsp;Giovanni Ristori ,&nbsp;Marco Salvetti ,&nbsp;Gianmarco Bellucci","doi":"10.1016/j.msard.2025.106535","DOIUrl":"10.1016/j.msard.2025.106535","url":null,"abstract":"<div><div>Recent research on the impact of gut microbiota on multiple sclerosis (MS) has been extensive; however, the role of microbial composition in other body interfaces, such as the mouth and the skin, has received much less attention. In a first step towards addressing this gap, we used Mendelian Randomization (MR), an analytical approach using genetic variants as proxies for environmental exposures to estimate the causal relationship between a risk factor and an outcome.</div><div>Here, we performed a two-sample MR analysis to assess the link between oral and skin microbiome composition and both MS risk and severity. Exposure data were extracted from summary statistics of two large genome-wide association studies (GWAS) assessing the influence of host genetics on the microbiome composition of the oral cavity and skin. Outcome data derived from the largest GWAS on MS susceptibility and the recent GWAS on MS severity. After stringent instrumental variant selection, we applied inverse-variance-weighted (IVW) and Wald’s ratio as primary MR methods, MR EGGER to control for horizontal pleiotropy, and checked directionality through Steiger’s test.</div><div>We found that the relative abundance of <em>Veillonella</em> genus in the skin may enhance MS risk, while no significant association between oral composition and MS susceptibility emerged. Furthermore, we found the <em>Gammaproteobacteria</em> class in the skin is associated with MS severity. We also identified suggestive, protective signals from different oral microbial strains (<em>Bacilli</em> class, <em>Porphyromonas</em> genus, <em>Proteobacteria</em> phylum and <em>Veillonella dispar</em> species).</div><div>Overall, our findings provide preliminary evidence supporting the hypothesis that skin microbiota might contribute to MS risk, and both oral and skin microbial composition could affect disease severity, broadening the relevance of dysbiosis beyond the gut in MS etiopathogenesis.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"100 ","pages":"Article 106535"},"PeriodicalIF":2.9,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Radiologically Isolated Syndrome and Multiple Sclerosis Prodrome: A case report and review of the literature","authors":"Charalampos Tzempetzis ,&nbsp;Chrysanthi Tsimakidi ,&nbsp;Dionysia Gkougka ,&nbsp;Maria Gontika","doi":"10.1016/j.msard.2025.106538","DOIUrl":"10.1016/j.msard.2025.106538","url":null,"abstract":"<div><h3>Background</h3><div>Radiologically isolated syndrome (RIS) represents a preclinical stage in multiple sclerosis (MS), marked by incidental, asymptomatic MRI findings of demyelination. While adult RIS is well-defined, pediatric RIS remains largely uncharted in terms of prevalence, clinical significance, and risk of progression.</div></div><div><h3>Methods</h3><div>This case-based analysis details the patient’s clinical history, imaging, and laboratory findings, alongside a comprehensive literature review on ped-RIS and its association with epilepsy and pediatric-onset MS.</div></div><div><h3>Results</h3><div>A 17-year-old female developed focal seizures at 15. Brain MRI revealed typical demyelinating lesions and lumbar puncture showed intrathecal oligoclonal bands (OCBs). Similar to adults, children with ped-RIS face a substantial risk of clinical conversion, influenced by biomarkers like neurofilament light chain and OCBs. Epilepsy may be an underrecognized MS prodromal or early symptom. No formal ped-RIS criteria or treatment consensus exist.</div></div><div><h3>Conclusions</h3><div>Expanding POMS registries and refining ped-RIS criteria are crucial for improving early intervention and long-term outcomes.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"100 ","pages":"Article 106538"},"PeriodicalIF":2.9,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocrelizumab for pediatric relapsing multiple sclerosis","authors":"Raed Alroughani ,&nbsp;Malak AlMojel ,&nbsp;Jasem Al-Hashel ,&nbsp;Samar Farouk Ahmed","doi":"10.1016/j.msard.2025.106539","DOIUrl":"10.1016/j.msard.2025.106539","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the effectiveness and safety of Ocrelizumab treatment for Pediatric-onset multiple sclerosis (POMS)</div></div><div><h3>Background</h3><div>POMS patients tend to have a higher rate of relapses and progression to secondary progressive course at earlier age compared to adult-onset MS. Although Ocrelizumab, a recombinant humanized anti-CD20 monoclonal IgG1, approved by FDA and EMA for adult patients with multiple sclerosis (AOMS), limited data in the literature is found in regards to its efficacy and safety in POMS subsets.</div></div><div><h3>Method</h3><div>A retrospective study was conducted on POMS patients who had Ocrelizumab treatment initiated at an age younger than 18 years old with at least one year of follow-up were included. The primary end-point was the proportion of relapse-free patients at the end of observational period. The secondary end-points were the change of annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, and proportion of patients with no MRI activity (new/enlarging T2 lesions and gadolinium (Gd) enhancing lesions).</div></div><div><h3>Results</h3><div>Of the 24 POMS patients enrolled in the study, 58.3 % were females with a mean age of 16.33 years. Prior to the administration of Ocrelizumab, all patients had clinical and radiological activities, of whom 23 were naïve and one had prior therapy. The median duration of follow-up under Ocrelizumab was 15 months. At the end of follow-up visits, 91.7 % of patients were relapse-free, with a decrease in the mean ARR from 1.08 to 0.08; <em>p</em> &lt; 0.001. Nonetheless, only one patient (4.2 %) had MRI activity during the treatment course. Mean EDSS was stabilized in 75 % of patient and improved in 16.7 % patients. None of the patients had serious side effects</div></div><div><h3>Conclusion</h3><div>Ocrelizumab can be considered a safe and effective treatment for POMS with RRMS.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"100 ","pages":"Article 106539"},"PeriodicalIF":2.9,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144137874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}